LSE - Delayed Quote DKK

Bavarian Nordic A/S (0DPB.L)

320.20
+14.27
+(4.66%)
As of July 22 at 8:35:04 AM GMT+1. Market Open.
Loading Chart for 0DPB.L
  • Previous Close 305.93
  • Open 323.40
  • Bid --
  • Ask --
  • Day's Range 318.40 - 326.90
  • 52 Week Range 171.45 - 410.70
  • Volume 10,522
  • Avg. Volume 44,021
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com

1,645

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 0DPB.L

View More

Performance Overview: 0DPB.L

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

0DPB.L
69.10%
MSCI WORLD (^990100-USD-STRD)
2.45%

1-Year Return

0DPB.L
0.00%
MSCI WORLD (^990100-USD-STRD)
11.04%

3-Year Return

0DPB.L
150.60%
MSCI WORLD (^990100-USD-STRD)
40.63%

5-Year Return

0DPB.L
70.64%
MSCI WORLD (^990100-USD-STRD)
90.08%

Compare To: 0DPB.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0DPB.L

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.20%

  • Return on Assets (ttm)

    6.65%

  • Return on Equity (ttm)

    12.16%

  • Revenue (ttm)

    6.23B

  • Net Income Avi to Common (ttm)

    1.32B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.24B

  • Total Debt/Equity (mrq)

    1.01%

  • Levered Free Cash Flow (ttm)

    -2.87B

Research Analysis: 0DPB.L

View More

Company Insights: 0DPB.L

Research Reports: 0DPB.L

View More